×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Xencor Appoints Bart Cornelissen as Chief Financial Officer
Business Wire
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and...
2 weeks ago
Death in Cancer Drug Trial Hinders Xencor’s Shares
Los Angeles Business Journal
Death in Cancer Drug Trial Hinders Xencor's Shares ... After reporting its fourth-quarter and full-year financials, Xencor Inc. sustained a steep...
1 month ago
Xencor to Host Webcast to Review Fourth Quarter and Full Year 2023 Financial Results and Provide Vudalimab ...
Yahoo Finance
PASADENA, Calif., February 20, 2024--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered...
2 months ago
Xencor pulls back from Genentech cancer pact to cut costs as CytomX drops ex-AbbVie ADC
Fierce Biotech
Xencor pulls back from Genentech cancer pact to cut costs as CytomX drops ex-AbbVie ADC ... Xencor and CytomX Therapeutics have taken a scalpel to...
5 months ago
Xencor Becomes Oversold (XNCR)
Nasdaq
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful.
1 week ago
USPTO Granted Remand in Important Antibody Written Description Case
Patently-O
by Dennis Crouch. The Federal Circuit has remanded the Xencor appeal — allowing USPTO leadership an opportunity to re-focus on the written...
3 months ago
Fed. Circ. Sends Xencor Antibody Patent Case Back To USPTO
Law360
The Federal Circuit has granted the U.S. Patent and Trademark Office's bid to send Xencor Inc.'s application for an antibody patent back for...
3 months ago
Xencor Inc Announces CFO Transition and Executive Compensation Plan - TipRanks.com
Tipranks
Xencor Inc (XNCR) has provided an update. John Kuch is set to retire from his CFO position at Xencor, Inc. on March 31, 2024, and Bart...
2 weeks ago
Xencor Inc (XNCR) Reports Mixed Financial Results for Q4 and Full Year 2023
Yahoo Finance
On February 27, 2024, Xencor Inc (NASDAQ:XNCR) released its 8-K filing, detailing its financial results for the fourth quarter and full year...
2 months ago
Xencor Reports Fourth Quarter and Full Year 2023 Financial Results
Business Wire
Xencor is advancing vudalimab, a selective dual checkpoint inhibitor, in multiple clinical studies, including a Phase 2 monotherapy study (Study...
2 months ago